VTRS logo

Viatris Inc. (VTRS)

$16.88

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on VTRS

Market cap

$19.39B

EPS

-0.4

P/E ratio

--

Price to sales

1.32

Dividend yield

2.844%

Beta

0.894378

Price on VTRS

Previous close

$16.94

Today's open

$16.81

Day's range

$16.67 - $17.02

52 week range

$9.43 - $18.39

Profile about VTRS

CEO

Scott A. Smith

Employees

32000

Headquarters

Canonsburg, PA

Exchange

Nasdaq Global Select

Shares outstanding

1.15B

Issue type

Common Stock

VTRS industries and sectors

Healthcare

Pharmaceuticals

News on VTRS

17 Ideal 'Safer' Buyable August Dogs Dug Up After 10 Years

I analyze 89 top Ten-Year Collected Dividend Dogs, focusing on yield-based strategies and safety via free cash flow coverage. Ten-year top dividend dogs project average net gains of 39.61% by August 2027, with risk profiles generally below market volatility. Seventeen 'safer' dogs meet the ideal of annual dividends from $1K invested exceeding share price, signaling strong income potential.

news source

Seeking Alpha • Aug 28, 2026

news preview

3 Generic Drug Stocks to Watch Amid Improving Industry Trends

The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.

news source

Zacks Investment Research • Aug 27, 2026

news preview

Here's Why Viatris (VTRS) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

news source

Zacks Investment Research • Aug 18, 2026

news preview

Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Viatris (VTRS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

news source

Zacks Investment Research • Aug 6, 2026

news preview

VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump

Viatris tops Q2 earnings and revenue estimates as Greater China sales surge 21%, helping lift results and prompting a higher 2026 financial outlook.

news source

Zacks Investment Research • Aug 6, 2026

news preview

Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript

Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Aug 6, 2026

news preview

Viatris Reports Second-Quarter 2026 Financial Results

Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025 Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025 Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn LoTM Announces Sale of Global Rights to Tyrvaya® Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x Raises 2026 Financial Guidance Midpoints for All Metrics [1] PITTSBURGH, Aug. 6, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced its second-quarter 2026 financial results. Executive Commentary "Our second-quarter results reflect another quarter of strong execution and reinforce the momentum we're building across our business," said Scott A.

news source

PRNewsWire • Aug 6, 2026

news preview

Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook

Harrow Inc. (NASDAQ:HROW) on Thursday agreed to acquire Tyrvaya (varenicline solution) nasal spray 0.03 mg from Viatris Inc. (NASDAQ:VTRS).

news source

Benzinga • Aug 6, 2026

news preview

Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates

Viatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.62 per share a year ago.

news source

Zacks Investment Research • Aug 6, 2026

news preview

Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Beyond analysts' top-and-bottom-line estimates for Viatris (VTRS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

news source

Zacks Investment Research • Aug 5, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Viatris Inc.

Open an M1 investment account to buy and sell Viatris Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in VTRS on M1